DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring systems for use by people with diabetes and by healthcare providers. Co.'s products include: DecCom G6®, which allows Co.'s transmitter to run an algorithm to generate a glucose value and to communicate to a patient's mobile device; DexCom G4® PLATINUM, which is used to adjust therapy and to educate and motivate patients to modify their behavior after viewing the effects that specific foods, exercise, stress and medications have on their glucose levels; and DexCom Share®, which transmits glucose information to the mobile devices of designated recipients. The DXCM stock yearly return is shown above.
The yearly return on the DXCM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DXCM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|